1.87
0.53%
-0.010
After Hours:
1.80
-0.07
-3.74%
PAVmed Inc stock is currently priced at $1.87, with a 24-hour trading volume of 27,425.
It has seen a -0.53% decreased in the last 24 hours and a -13.82% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.86 pivot point. If it approaches the $1.92 resistance level, significant changes may occur.
PAVmed Inc Stock (PAVM) Financials Data
PAVmed Inc (PAVM) Revenue 2024
PAVM reported a revenue (TTM) of $1.51 million for the quarter ending September 30, 2023.
PAVmed Inc (PAVM) Net Income 2024
PAVM net income (TTM) was -$70.60 million for the quarter ending September 30, 2023, a +17.66% increase year-over-year.
PAVmed Inc (PAVM) Cash Flow 2024
PAVM recorded a free cash flow (TTM) of -$57.34 million for the quarter ending September 30, 2023, a +21.94% increase year-over-year.
PAVmed Inc (PAVM) Earnings per Share 2024
PAVM earnings per share (TTM) was -$10.65 for the quarter ending September 30, 2023, a +29.70% growth year-over-year.
PAVmed Inc Stock (PAVM) Latest News
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
Zacks Investment Research
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Benzinga
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
New Strong Buy Stocks for March 27th
Zacks Investment Research
Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Benzinga
About PAVmed Inc
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Cap:
|
Volume (24h):